Home Cart Sign in  
Chemical Structure| 1236199-60-2 Chemical Structure| 1236199-60-2

Structure of Tinostamustine
CAS No.: 1236199-60-2

Chemical Structure| 1236199-60-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

EDO-S101 is a pan HDAC inhibitor and inhibits HDAC1, HDAC2 and HDAC3 with IC50 values of 9, 9 and 25 nM, respectively.

Synonyms: EDO-s101; NL-101

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tinostamustine

CAS No. :1236199-60-2
Formula : C19H28Cl2N4O2
M.W : 415.36
SMILES Code : O=C(NO)CCCCCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C
Synonyms :
EDO-s101; NL-101
MDL No. :MFCD28400036
InChI Key :GISXTRIGVCKQBX-UHFFFAOYSA-N
Pubchem ID :46836227

Safety of Tinostamustine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tinostamustine

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
OCI-LY10 0.625-4.994 μM 48 hours NL101 significantly inhibited B cell lymphoma proliferation through induction of cell cycle arrest and apoptosis. PMC7847677
Ramos 0.625-4.994 μM 48 hours NL101 significantly inhibited B cell lymphoma proliferation through induction of cell cycle arrest and apoptosis. PMC7847677

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Female CD1-nu/nu mice Subcutaneous injection of U251, U87MG, and T98G cells Intravenous injection 60 mg/kg Days 1, 8, and 15 q28 days Tinostamustine monotherapy demonstrated an anti-tumor effect reducing tumor weight and increased the antitumor effects of RT NL-101
NOD-SCID mice Lymphoma xenograft model Intravenous injection 15 mg/kg Every other day for 2 weeks NL101 significantly inhibited lymphoma growth and prolonged the survival of xenograft model mice. NL-101
B-NSG mice MV4-11-luc xenograft model Intravenous injection 12 mg/kg Twice (day 11–12) NL101 alone showed a modest reduction, but combination with BMN673 effectively delayed AML development and prolonged survival. NL-101

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05432375 Glioblastoma Multiforme EARLY_PHASE1 ACTIVE_NOT_RECRUITING 2024-11-30 Hospital Universitario Vall d'... More >>Hebron, Barcelona, Spain, Barcelona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain, Madrid, Spain|South Texas Accelerated Research Therapeutics (START), Madrid, Spain|Kantonsspital, St Gallen, Switzerland|University Hospital, Zürich, Switzerland Less <<
NCT03903458 Malignant Melanoma PHASE1 UNKNOWN 2024-03-15 Kantonsspital Graubünden, Chur... More >>, 7000, Switzerland|Cantonal Hospital St.Gallen, St.Gallen, 9007, Switzerland Less <<
NCT02576496 Hematological Malignancies|Mul... More >>tiple Myeloma|Hodgkin's Lymphoma|Cutaneous T Cell Lymphoma Less << PHASE1 COMPLETED 2023-11-21 Mayo Clinic, Phoenix, Arizona,... More >> 85054, United States|Mayo Clinic Cancer Center, Jacksonville, Florida, 32224, United States|Columbia University Medical Center, New York, New York, 10019, United States|University Hospitals Cleveland Seidman Cancer Center, Cleveland, Ohio, 44106, United States|CHU de Caen, Caen, CS 3001, France|CHU ESTAING Service de thérapie Cellulaire et hématologique Clinique, Clermont Ferrand, 63000, France|CHU Lille Service des Maladies du Sang, Lille, 59037, France|Hopital Haut Leveque, Pessac, 33604, France|Centre hospitalier Lyon Sud, Pierre Bénite, 69495, France|University Hospital of Ulm, Department of Internal Medicine III, Ulm, 89081, Germany|Institute of Hematology "L. A. Seràgnoli", University of Bologna, Bologna, 40138, Italy|National Cancer Institute, Fondazione 'G. Pascale', Naples, I-80131, Italy|VU medisch centrum, Amsterdam, 1081 HV, Netherlands|Erasmus MC, Rotterdam, 3015 GD, Netherlands|Institut Català d'Oncologia de Barcelona, Hospitalet de Llobregat, Barcelona, 08908, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Marqués de Valdecilla, Santander, 39008, Spain|Kantonsspital St.Gallen, St.Gallen, 9007, Switzerland Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.04mL

2.41mL

1.20mL

24.08mL

4.82mL

2.41mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories